- Home
- MODD vs HOWL Comparison
MODD vs HOWL Comparison
Compare MODD & HOWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- HOWL
- Stock Information
- Founded
- MODD 1998
- HOWL 2017
- Country
- MODD United States
- HOWL United States
- Employees
- MODD N/A
- HOWL N/A
- Industry
- MODD Industrial Specialties
- HOWL Biotechnology: Pharmaceutical Preparations
- Sector
- MODD Health Care
- HOWL Health Care
- Exchange
- MODD Nasdaq
- HOWL Nasdaq
- Market Cap
- MODD 46.3M
- HOWL 47.1M
- IPO Year
- MODD N/A
- HOWL 2021
- Fundamental
- Price
- MODD $0.70
- HOWL $1.27
- Analyst Decision
- MODD
- HOWL Strong Buy
- Analyst Count
- MODD 0
- HOWL 3
- Target Price
- MODD N/A
- HOWL $8.33
- AVG Volume (30 Days)
- MODD 70.8K
- HOWL 175.6K
- Earning Date
- MODD 08-14-2025
- HOWL 08-14-2025
- Dividend Yield
- MODD N/A
- HOWL N/A
- EPS Growth
- MODD N/A
- HOWL N/A
- EPS
- MODD N/A
- HOWL N/A
- Revenue
- MODD N/A
- HOWL N/A
- Revenue This Year
- MODD N/A
- HOWL N/A
- Revenue Next Year
- MODD N/A
- HOWL N/A
- P/E Ratio
- MODD N/A
- HOWL N/A
- Revenue Growth
- MODD N/A
- HOWL N/A
- 52 Week Low
- MODD $0.63
- HOWL $0.60
- 52 Week High
- MODD $2.65
- HOWL $4.18
- Technical
- Relative Strength Index (RSI)
- MODD 43.81
- HOWL 51.42
- Support Level
- MODD $0.69
- HOWL $1.25
- Resistance Level
- MODD $0.75
- HOWL $1.40
- Average True Range (ATR)
- MODD 0.04
- HOWL 0.08
- MACD
- MODD 0.00
- HOWL 0.01
- Stochastic Oscillator
- MODD 16.48
- HOWL 53.57
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.